Financial Performance Summary

GlaxoSmithKline Pharmaceuticals Ltd (GSK India) announced its financial results for the first quarter ended 30th June 2026.

Revenue: INR 924 crores, representing 15% year-over-year growth.

Profit After Tax (PAT): INR 253 crores, showing 24% year-over-year growth.

EBITDA Margin: Stood at 32% for the quarter.

Segment-Wise Performance Breakdown

General Medicines Portfolio

  • Delivered strong growth during the quarter
  • Top five promoted brands outperformed the market (Evolution Index >100; Source: IQVIA)
  • Key promoted brands including Augmentin, Ceftum, and T-Bact reinforced their leadership positions
  • Growth driven by deeper scientific and in-clinic engagement, omnichannel execution, and pricing measures

Respiratory Portfolio

  • Continued to further the management of chronic respiratory diseases
  • Nucala (mepolizumab) benefitted a large number of patients
  • Trelegy Ellipta gained traction through new access pathways

Vaccines Business

  • Grew through continued leadership in the self-pay private paediatric vaccines market
  • Led by Infanrix Hexa and Fluarix Tetra
  • Focus on elderly patient-cohorts with underlying Cardiovascular and Metabolic Diseases (CVMD) led to stronger endorsement from healthcare professionals
  • Resulted in higher vaccinations with Shingrix (Recombinant Herpes Zoster Vaccine, Adjuvanted)

Oncology Business

  • Led by specialised therapies Jemperli (dostarlimab) and Zejula (niraparib)
  • Has grown significantly since its launch in August 2025
  • Jemperli is now the leading immunotherapy for first line primary advanced and recurrent endometrial cancer
  • Zejula is among the top PARP inhibitors in the maintenance treatment of recurrent ovarian cancer (Source: IPSOS MAT December 2025)
  • Both therapies have touched the lives of a growing number of women suffering from gynecological malignancies

Operational and Strategic Updates

Supply Chain Improvements

  • Made progress in strengthening supply chain resilience through diversified sourcing
  • Enhanced contingency planning and improved end-to-end visibility
  • Substantially mitigated disruptions experienced in recent quarters

Pipeline Developments

  • Blenrep (belantamab mafodotin) is set for launch - an anti-BCMA ADC therapy indicated for second-line treatment in relapsed or refractory multiple myeloma in adults
  • Arexvy has received marketing authorisation - a vaccine to prevent lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults over 60 years of age and older adults (50 to 59 years) at high-risk

Management Commentary

Mr. Bhushan Akshikar, Managing Director, GSK India, commented: "GSK India's broad-based growth demonstrates the resilience of the core General Medicines and Vaccines portfolio and the growing contribution of the innovative business. This growth was enabled by a relentless focus on scientific excellence, sharper execution in the field and meaningful investments in technology and talent development. With a strong innovation pipeline and launch opportunities ahead, we are well-positioned to deliver sustainable growth and meaningful impact for millions of patients in India."

Performance Drivers

  • Portfolio transformation strategy
  • Execution excellence
  • Favourable base effect from the comparable period last year
  • Scientific engagement and omnichannel execution
  • Pricing measures
  • New access pathways for existing products

Future Outlook

  • Strong innovation pipeline with launch opportunities ahead
  • Commitment to expanding access and patient reach for oncology therapies
  • Preparation for key pipeline launches including Blenrep and Arexvy
  • Focus on delivering sustainable growth and meaningful impact for patients